EP3669971A1 - Diffusion device - Google Patents
Diffusion device Download PDFInfo
- Publication number
- EP3669971A1 EP3669971A1 EP18215661.2A EP18215661A EP3669971A1 EP 3669971 A1 EP3669971 A1 EP 3669971A1 EP 18215661 A EP18215661 A EP 18215661A EP 3669971 A1 EP3669971 A1 EP 3669971A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- section
- housing
- blood
- cylindrical shell
- component part
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1698—Blood oxygenators with or without heat-exchangers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1621—Constructional aspects thereof
- A61M1/1623—Disposition or location of membranes relative to fluids
- A61M1/1625—Dialyser of the outside perfusion type, i.e. blood flow outside hollow membrane fibres or tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/08—Flow guidance means within the module or the apparatus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/10—Specific supply elements
- B01D2313/105—Supply manifolds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/21—Specific headers, end caps
Definitions
- the present disclosure relates to a diffusion device, such as a blood oxygenator or gas exchanger, having improved flow characteristics.
- Diffusion devices used as blood oxygenators or gas exchangers generally encompass a tubular casing with a bundle of hollow fiber membranes arranged in the casing in a way that a seal is provided between the first flow space formed by the fiber cavities and a second flow space surrounding the membranes on the outside.
- One problem with the design of the blood inflow connected to the second flow space is to distribute the liquid evenly between the individual fibers of the hollow fiber bundle, and to avoid the formation of dead zones in the inlet, i.e. areas where the flow velocity is about zero. Blood clots may form in such dead zones, and after completion of a treatment, some of the patient's blood remains there. As the diameter of the inlet is smaller than the diameter of the fiber bundle, the velocity of the blood-flow is reduced. The design of the inlet therefore is of particular importance to ensure optimal operation of the device.
- a diffusion device having improved flow characteristics.
- the device comprises a cylindrical housing, a plurality of hollow fiber membranes arranged within the housing, and end caps sealing the mouths of the housing.
- the diffusion device of the present disclosure comprises a cylindrical housing.
- the cylindrical housing provides an outlet for blood arranged on the outer wall of the housing.
- the blood outlet is located near an end of the cylindrical housing opposite to a first end cap.
- the cylindrical housing is comprised of polycarbonate.
- a plurality of semi-permeable hollow fiber membranes is disposed inside the housing within a cylindrical shell adjoining the inner wall of the housing.
- the semi-permeable hollow fiber membranes are gas exchange membranes, i.e., they are permeable to gases like oxygen and carbon dioxide, but impermeable to liquids.
- the semi-permeable hollow fiber membranes are arranged in the form of hollow fiber mats wound on a cylindrical core.
- the hollow fiber mats form a cylindrical shell that contacts the inner surface of the cylindrical housing.
- the ends of the hollow fibers are open, so that a gas flow can be conducted through the lumen of the hollow fibers, i.e., from one mouth of the housing to the mouth opposite to it.
- blood flows on the outside of the hollow fibers, and gas can permeate through the wall of the hollow fibers in both directions.
- the flow space formed by the lumen of the hollow fibers is separated from the flow space on the outside of the hollow fibers by end walls.
- the end walls are formed by potting the fiber ends with a polyurethane resin. After the resin has hardened, the ends of the hollow fibers are cut off to re-open the lumen of the hollow fibers.
- the diffusion device comprises a first end cap sealing a first mouth of the housing.
- the end cap comprises an inlet for the introduction of blood into the housing, arranged axially in the center of the first end cap.
- a two-start thread which fits a standard blood-line connector is provided round the inlet.
- the inner surface of the end cap is rotationally symmetrical about the longitudinal axis of the inlet.
- the inlet is also coaxial to the longitudinal axis of the housing.
- the end cap also comprises an outlet for evacuating a gas from the diffusion device, e.g., a gas mixture comprising carbon dioxide.
- the diffusion device comprises a rotationally symmetric blood duct connecting the inlet to an inner perimeter of the cylindrical shell.
- the blood duct is defined by a first inner surface and a second inner surface.
- the first inner surface comprises, in the direction of increasing diameter, a first section taking the form of a cylinder or a truncated cone, and a second section connecting the first section and the inner perimeter of the cylindrical shell.
- the second section takes the form of a torus segment, with an angle ⁇ between the longitudinal axis of the cylindrical housing and a straight line (A) intersecting i) the longitudinal axis, ii) the intersection of the first section and the second section, and iii) the intersection of the second section and the inner perimeter of the cylindrical shell.
- the angle ⁇ is in the range of from 55° to 80°, and the maximum of a perpendicular distance (a) between the straight line (A) and the surface of the second section is in the range of from 0.5 to 1 mm. In one embodiment of the diffusion device of the present disclosure, the angle ⁇ is in the range of from 70° to 80°. In one embodiment, the radius of curvature of the second section is in the range of from 18 to 21 mm.
- the second inner surface spans the inner perimeter of the cylindrical shell, i.e., the second inner surface spans the complete cross-section of the hollow cylinder confined by the cylindrical shell.
- an angle ⁇ between the longitudinal axis of the cylindrical housing and a straight line (B) intersecting i) the longitudinal axis at its intersection with the second inner surface and ii) the intersection of the second inner surface and the inner perimeter of the cylindrical shell is in the range of from 55° to 80°, and the maximum of a perpendicular distance (b) between the straight line (B) and the surface of the second inner surface is in the range of from 0.5 to 1 mm.
- the angle ⁇ is in the range of from 70° to 80°.
- a distance (d) between the first inner surface and the second inner surface at the inner perimeter of the cylindrical shell is in the range of from 2 to 3 mm; and a minimal distance between the second section of the first inner surface and the second inner surface is not less than 1 mm. In one embodiment of the diffusion device, the minimal distance is 1.0 mm.
- the maximum of the perpendicular distance (a) is (0.5 ⁇ 0.05) mm; the maximum of the perpendicular distance (b) is (0.5 ⁇ 0.05) mm; and the minimal distance between the second section of the first inner surface and the second inner surface is (1 ⁇ 0.1) mm.
- the radius of curvature of the second inner surface is smaller at the center of the second inner surface than the radius of curvature opposite the second section of the first inner surface. In one embodiment, the radius of curvature opposite the second section of the first inner surface is in the range of from 22 to 26 mm. In a further embodiment, the radius of curvature at the center of the second inner surface is in the range of from 2 to 4 mm.
- the first section of the first inner surface takes the form of a cylinder. In another embodiment, the first section of the first inner surface takes the form of a truncated cone with an aperture in the range of from 0.1° to 2°.
- the rotationally symmetric blood duct is formed by assembling a first component part having an outer surface that provides the first inner surface of the blood duct and a second component part having an outer surface that provides the second inner surface of the blood duct.
- the outer surface of the first component part which provides the first inner surface of the blood duct features at least three protrusions and the outer surface of the second component part which provides the second inner surface of the blood duct features corresponding depressions.
- the protrusions and corresponding depressions are configured to interact upon assembly of the first and second component parts and determine the spacing between the first and second inner surfaces of the blood duct.
- four protrusions and four corresponding depressions are equally distributed over a circumference of the parts, i.e., at 0°, 90°, 180°, and 270°.
- the outer surface of the first component part which provides the first inner surface of the blood duct features at least three depressions and the outer surface of the second component part which provides the second inner surface of the blood duct features corresponding protrusions.
- the depressions and corresponding protrusions are configured to interact upon assembly of the first and second component parts and determine the spacing between the first and second inner surfaces of the blood duct.
- the first and second component parts are comprised of polycarbonate.
- An embodiment of the diffusion device of the present disclosure additionally comprises a second end cap sealing a second mouth of the housing, i.e. the mouth opposite the mouth with the first end cap.
- the second end cap provides an inlet for introducing a gas, e.g., air or oxygen, into the diffusion device.
- the housing and end caps of the device of the present disclosure are usually made of a transparent polymer, e.g. polyethylene, polypropylene, polyesters like PET or PBT, polymethyl(meth)acrylate, polystyrene (HIPS) or polycarbonate.
- the potting material for the hollow fiber membranes usually is polyurethane.
- the housing and caps are made of polycarbonate, the potting material forming the end walls is comprised of polyurethane.
- a plurality of semi-permeable hollow fiber membranes 120 is disposed inside the housing 110 within a cylindrical shell adjoining the inner wall of the housing 110.
- An inner perimeter 150 of the cylindrical shell defines a cavity within the housing 110.
- a rotationally symmetric blood duct 140 connects the inlet 131 to the inner perimeter 150 of the cylindrical shell.
- the blood duct 140 is defined by a first inner surface 141 and a second inner surface 145.
- the first inner surface 141 comprises, in the direction of increasing diameter, a first section 142 having the form of a truncated cone, and a second section 143 connecting the first section 142 and the inner perimeter 150 of the cylindrical shell.
- the second section 143 has the form of a torus segment.
- An angle ⁇ between the longitudinal axis 111 of the cylindrical housing 110 and a straight line A intersecting i) the longitudinal axis 111, ii) the intersection of the first section 142, and the second section 143, and iii) the intersection of the second section 143 and the inner perimeter 150 of the cylindrical shell is in the range of from 55° to 80°.
- the maximum of a perpendicular distance a between the straight line A and the surface of the second section 143 is in the range of from 0.5 to 1 mm.
- the second inner surface 145 spans the inner perimeter 150 of the cylindrical shell.
- An angle ⁇ between the longitudinal axis 111 of the cylindrical housing 110 and a straight line B intersecting i) the longitudinal axis 111 at its intersection with the second inner surface 145 and ii) the intersection of the second inner surface 145 and the inner perimeter 150 of the cylindrical shell is in the range of from 55° to 80°.
- the maximum of a perpendicular distance b between the straight line B and the surface of the second inner surface 145 is in the range of from 0.5 to 1 mm.
- a distance d between the first inner surface 141 and the second inner surface 145 at the inner perimeter 150 of the cylindrical shell is in the range of from 2 to 3 mm.
- a minimal distance between the second section 143 of the first inner surface 141 and the second inner surface 145 is not less than 1 mm.
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
- The present disclosure relates to a diffusion device, such as a blood oxygenator or gas exchanger, having improved flow characteristics.
- Diffusion devices used as blood oxygenators or gas exchangers generally encompass a tubular casing with a bundle of hollow fiber membranes arranged in the casing in a way that a seal is provided between the first flow space formed by the fiber cavities and a second flow space surrounding the membranes on the outside. One problem with the design of the blood inflow connected to the second flow space is to distribute the liquid evenly between the individual fibers of the hollow fiber bundle, and to avoid the formation of dead zones in the inlet, i.e. areas where the flow velocity is about zero. Blood clots may form in such dead zones, and after completion of a treatment, some of the patient's blood remains there. As the diameter of the inlet is smaller than the diameter of the fiber bundle, the velocity of the blood-flow is reduced. The design of the inlet therefore is of particular importance to ensure optimal operation of the device.
- It is an object of the present invention to provide a diffusion device with a more homogeneous blood flow within the device and no areas where the blood velocity is nearly zero (dead zones).
- According to one aspect of the invention, a diffusion device having improved flow characteristics is provided. The device comprises a cylindrical housing, a plurality of hollow fiber membranes arranged within the housing, and end caps sealing the mouths of the housing.
-
-
Figure 1 shows a schematic partial cross-sectional view of an embodiment of the diffusion device of the present disclosure; -
Figure 2 shows a cross-sectional view of another embodiment of the diffusion device of the present disclosure; -
Figure 3 shows a side view and a cross-sectional view of an assembly of two component parts providing the blood duct of an embodiment of the diffusion device of the present disclosure; -
Figure 4 shows a cross-sectional view of a first component part for providing the blood duct of an embodiment of the diffusion device of the present disclosure; -
Figure 5 shows a cross-sectional view of a second component part for providing the blood duct of an embodiment of the diffusion device of the present disclosure. - The diffusion device of the present disclosure comprises a cylindrical housing. In one embodiment, the cylindrical housing provides an outlet for blood arranged on the outer wall of the housing. In a further embodiment, the blood outlet is located near an end of the cylindrical housing opposite to a first end cap. In one embodiment, the cylindrical housing is comprised of polycarbonate.
- A plurality of semi-permeable hollow fiber membranes is disposed inside the housing within a cylindrical shell adjoining the inner wall of the housing.
- In one embodiment, the semi-permeable hollow fiber membranes are gas exchange membranes, i.e., they are permeable to gases like oxygen and carbon dioxide, but impermeable to liquids.
- In a further embodiment, the semi-permeable hollow fiber membranes are arranged in the form of hollow fiber mats wound on a cylindrical core. The hollow fiber mats form a cylindrical shell that contacts the inner surface of the cylindrical housing. The ends of the hollow fibers are open, so that a gas flow can be conducted through the lumen of the hollow fibers, i.e., from one mouth of the housing to the mouth opposite to it. During operation of the diffusion device, blood flows on the outside of the hollow fibers, and gas can permeate through the wall of the hollow fibers in both directions. In one embodiment of the device, the flow space formed by the lumen of the hollow fibers is separated from the flow space on the outside of the hollow fibers by end walls. In one embodiment, the end walls are formed by potting the fiber ends with a polyurethane resin. After the resin has hardened, the ends of the hollow fibers are cut off to re-open the lumen of the hollow fibers.
- The diffusion device comprises a first end cap sealing a first mouth of the housing. The end cap comprises an inlet for the introduction of blood into the housing, arranged axially in the center of the first end cap. In one embodiment, a two-start thread which fits a standard blood-line connector is provided round the inlet. The inner surface of the end cap is rotationally symmetrical about the longitudinal axis of the inlet. The inlet is also coaxial to the longitudinal axis of the housing. In a further embodiment, the end cap also comprises an outlet for evacuating a gas from the diffusion device, e.g., a gas mixture comprising carbon dioxide.
- The diffusion device comprises a rotationally symmetric blood duct connecting the inlet to an inner perimeter of the cylindrical shell. The blood duct is defined by a first inner surface and a second inner surface.
- The first inner surface comprises, in the direction of increasing diameter, a first section taking the form of a cylinder or a truncated cone, and a second section connecting the first section and the inner perimeter of the cylindrical shell. The second section takes the form of a torus segment, with an angle α between the longitudinal axis of the cylindrical housing and a straight line (A) intersecting i) the longitudinal axis, ii) the intersection of the first section and the second section, and iii) the intersection of the second section and the inner perimeter of the cylindrical shell. In the diffusion device of the present disclosure, the angle α is in the range of from 55° to 80°, and the maximum of a perpendicular distance (a) between the straight line (A) and the surface of the second section is in the range of from 0.5 to 1 mm. In one embodiment of the diffusion device of the present disclosure, the angle α is in the range of from 70° to 80°. In one embodiment, the radius of curvature of the second section is in the range of from 18 to 21 mm.
- The second inner surface spans the inner perimeter of the cylindrical shell, i.e., the second inner surface spans the complete cross-section of the hollow cylinder confined by the cylindrical shell. In the diffusion device of the present disclosure, an angle β between the longitudinal axis of the cylindrical housing and a straight line (B) intersecting i) the longitudinal axis at its intersection with the second inner surface and ii) the intersection of the second inner surface and the inner perimeter of the cylindrical shell is in the range of from 55° to 80°, and the maximum of a perpendicular distance (b) between the straight line (B) and the surface of the second inner surface is in the range of from 0.5 to 1 mm. In one embodiment of the diffusion device of the present disclosure, the angle β is in the range of from 70° to 80°.
- In the diffusion device of the present disclosure, a distance (d) between the first inner surface and the second inner surface at the inner perimeter of the cylindrical shell is in the range of from 2 to 3 mm; and a minimal distance between the second section of the first inner surface and the second inner surface is not less than 1 mm. In one embodiment of the diffusion device, the minimal distance is 1.0 mm.
- In one embodiment of the diffusion device of the present disclosure, the maximum of the perpendicular distance (a) is (0.5 ± 0.05) mm; the maximum of the perpendicular distance (b) is (0.5 ± 0.05) mm; and the minimal distance between the second section of the first inner surface and the second inner surface is (1 ± 0.1) mm.
- In one embodiment of the diffusion device of the present disclosure, the radius of curvature of the second inner surface is smaller at the center of the second inner surface than the radius of curvature opposite the second section of the first inner surface. In one embodiment, the radius of curvature opposite the second section of the first inner surface is in the range of from 22 to 26 mm. In a further embodiment, the radius of curvature at the center of the second inner surface is in the range of from 2 to 4 mm.
- In one embodiment of the diffusion device of the present disclosure, the first section of the first inner surface takes the form of a cylinder. In another embodiment, the first section of the first inner surface takes the form of a truncated cone with an aperture in the range of from 0.1° to 2°.
- In one embodiment of the diffusion device of the present disclosure, the rotationally symmetric blood duct is formed by assembling a first component part having an outer surface that provides the first inner surface of the blood duct and a second component part having an outer surface that provides the second inner surface of the blood duct.
- In one embodiment, the outer surface of the first component part which provides the first inner surface of the blood duct features at least three protrusions and the outer surface of the second component part which provides the second inner surface of the blood duct features corresponding depressions. The protrusions and corresponding depressions are configured to interact upon assembly of the first and second component parts and determine the spacing between the first and second inner surfaces of the blood duct. In a further embodiment, four protrusions and four corresponding depressions are equally distributed over a circumference of the parts, i.e., at 0°, 90°, 180°, and 270°.
- In one embodiment, the outer surface of the first component part which provides the first inner surface of the blood duct features at least three depressions and the outer surface of the second component part which provides the second inner surface of the blood duct features corresponding protrusions. The depressions and corresponding protrusions are configured to interact upon assembly of the first and second component parts and determine the spacing between the first and second inner surfaces of the blood duct.
- In one embodiment of the diffusion device of the present disclosure, the first and second component parts are comprised of polycarbonate.
- An embodiment of the diffusion device of the present disclosure additionally comprises a second end cap sealing a second mouth of the housing, i.e. the mouth opposite the mouth with the first end cap. The second end cap provides an inlet for introducing a gas, e.g., air or oxygen, into the diffusion device.
- The housing and end caps of the device of the present disclosure are usually made of a transparent polymer, e.g. polyethylene, polypropylene, polyesters like PET or PBT, polymethyl(meth)acrylate, polystyrene (HIPS) or polycarbonate. The potting material for the hollow fiber membranes usually is polyurethane. In one embodiment of the device of the invention, the housing and caps are made of polycarbonate, the potting material forming the end walls is comprised of polyurethane.
- The diffusion device of the present disclosure will now be described in more detail referring to the accompanying drawings. It is to be understood that the drawings are not intended to limit the scope of the present disclosure and are merely an illustration of preferred embodiments of the device.
-
Figure 1 shows a partial cross-sectional view of an embodiment of thediffusion device 100 proposed in the present disclosure. As thedevice 100 is rotationally symmetrical to thelongitudinal axis 111 of thedevice 100, only one half of the cross-section is shown inFigure 1 . As shown inFigure 1 , thedevice 100 comprises aninlet 131 for blood, arranged axially in the center of afirst end cap 130 of thedevice 100. The inner surface of theend cap 130 is rotationally symmetrical about the longitudinal axis of the inlet, which is also the longitudinal axis of theend cap 130 and thelongitudinal axis 111 of thehousing 110, theinlet 131 is coaxial to thelongitudinal axis 111 of thehousing 110. - A plurality of semi-permeable
hollow fiber membranes 120 is disposed inside thehousing 110 within a cylindrical shell adjoining the inner wall of thehousing 110. Aninner perimeter 150 of the cylindrical shell defines a cavity within thehousing 110. - A rotationally
symmetric blood duct 140 connects theinlet 131 to theinner perimeter 150 of the cylindrical shell. Theblood duct 140 is defined by a firstinner surface 141 and a secondinner surface 145. - The first
inner surface 141 comprises, in the direction of increasing diameter, afirst section 142 having the form of a truncated cone, and asecond section 143 connecting thefirst section 142 and theinner perimeter 150 of the cylindrical shell. Thesecond section 143 has the form of a torus segment. An angle α between thelongitudinal axis 111 of thecylindrical housing 110 and a straight line A intersecting i) thelongitudinal axis 111, ii) the intersection of thefirst section 142, and thesecond section 143, and iii) the intersection of thesecond section 143 and theinner perimeter 150 of the cylindrical shell is in the range of from 55° to 80°. The maximum of a perpendicular distance a between the straight line A and the surface of thesecond section 143 is in the range of from 0.5 to 1 mm. - The second
inner surface 145 spans theinner perimeter 150 of the cylindrical shell. An angle β between thelongitudinal axis 111 of thecylindrical housing 110 and a straight line B intersecting i) thelongitudinal axis 111 at its intersection with the secondinner surface 145 and ii) the intersection of the secondinner surface 145 and theinner perimeter 150 of the cylindrical shell is in the range of from 55° to 80°. The maximum of a perpendicular distance b between the straight line B and the surface of the secondinner surface 145 is in the range of from 0.5 to 1 mm.
a distance d between the firstinner surface 141 and the secondinner surface 145 at theinner perimeter 150 of the cylindrical shell is in the range of from 2 to 3 mm. A minimal distance between thesecond section 143 of the firstinner surface 141 and the secondinner surface 145 is not less than 1 mm. -
Figure 2 shows a cross-sectional view of another embodiment of thediffusion device 100 of the present disclosure. Enlarged detail views X and Y of the device are also shown. The mouths ofcylindrical housing 110 are covered by afirst end cap 130 and asecond end cap 500, respectively. Thehousing 110 has ablood inlet 115 positioned on the outer wall of the hosing adjacent to thesecond end cap 500. Thefirst end cap 130 features ablood inlet 131 and agas outlet 132, the second end cap 500 agas inlet 501.Hollow fibers 120 are arranged within thehousing 110 within a cylindrical shell bordering on the inner wall surface of thehousing 110 and limited byperimeter 150.End walls 400 separate a first flow space formed by the lumen of thehollow fibers 120 and cavities defined by thesecond end cap 500 and thefirst end cap 130 from a second flow space defined byblood inlet 131,blood duct 140, and the space outside thehollow fibers 120 within the circular shell, i.e., between the inner wall surface of thehousing 110 and theperimeter 150. A core formed by an assembly of twocomponent parts perimeter 150.Component part 301 features fourdepressions 310,component part 302 has fourcorresponding protrusions 311. Theprotrusions 311 enter thedepressions 310 upon assembly of the core and together formblood duct 140,component part 301 defining afirst surface 141; andcomponent part 302 defining asecond surface 145 of theblood duct 140. -
Figure 3 shows a side view and a cross-sectional view of an assembly of twocomponent parts blood duct 140 of an embodiment of the diffusion device of the present disclosure.Component part 301 features fourdepressions 310,component part 302 has fourcorresponding protrusions 311. Theprotrusions 311 enter thedepressions 310 upon assembly of the core and together formblood duct 140. -
Figure 4 shows a cross-sectional view of afirst component part 301 for providing the blood duct of an embodiment of the diffusion device of the present disclosure. Anouter surface 141 ofcomponent part 301 provides a first surface of the blood duct. Thesurface 141 has afirst section 142 and asecond section 143. In the embodiment shown, thefirst section 142 has the form of a frustrated cone having an aperture of 1°; and thesecond section 143 has the form of a torus segment with a radius of curvature of 19.5 mm.Component part 301 features fourdepressions 310 that are configured to interact with corresponding protrusions of a second component part. -
Figure 5 shows a cross-sectional view of asecond component part 302 for providing the blood duct of an embodiment of the diffusion device of the present disclosure and an enlarged detail view X ofcomponent part 302. Anouter surface 145 ofcomponent part 302 provides a second surface of the blood duct. In the embodiment shown, thesurface 145 has a smaller radius of curvature at its center than at its perimeter. The radius of curvature at the center ofsurface 145 is 3 mm, while the radius of curvature of thesurface 145 further away from its center is 24 mm.Component part 302 features fourprotrusions 311 that are configured to interact with corresponding protrusions of a second component part. -
- 100
- diffusion device
- 110
- cylindrical housing
- 111
- longitudinal axis of cylindrical housing
- 115
- blood outlet
- 120
- hollow fiber membranes/cylindrical shell
- 130
- first end cap
- 131
- blood inlet
- 132
- air outlet
- 140
- blood duct
- 141
- first inner surface
- 142
- first section of first inner surface
- 143
- second section of first inner surface
- 145
- second inner surface
- 150
- inner perimeter of cylindrical shell
- 301
- first component part
- 302
- second component part
- 310
- depression
- 311
- protrusion
- 400
- end wall
- 500
- second end cap
- 501
- air inlet
Claims (10)
- A diffusion device (100) comprisinga) a cylindrical housing (110);b) a plurality of semi-permeable hollow fiber membranes (120) disposed inside the housing (110) within a cylindrical shell adjoining the inner wall of the housing (110);c) a first end cap (130) sealing a first mouth of the housing (110) and comprising an inlet (131) for the introduction of blood into the housing (110), the inlet (131) being coaxial to the longitudinal axis (111) of the housing (110); andd) a rotationally symmetric blood duct (140) connecting the inlet (131) to an inner perimeter (150) of the cylindrical shell, the blood duct (140) being defined by a first inner surface (141) and a second inner surface (145),the first inner surface (141) comprising, in the direction of increasing diameter, a first section (142) taking the form of a cylinder or a truncated cone, and a second section (143) connecting the first section (142) and the inner perimeter (150) of the cylindrical shell, the second section (143) taking the form of a torus segment, with an angle α between the longitudinal axis (111) of the cylindrical housing (110) and a straight line (A) intersecting i) the longitudinal axis (111), ii) the intersection of the first section (142) and the second section (143), and iii) the intersection of the second section (143) and the inner perimeter (150) of the cylindrical shell being in the range of from 55° to 80°, and the maximum of a perpendicular distance (a) between the straight line (A) and the surface of the second section (143) being in the range of from 0.5 to 1 mm;the second inner surface (145) spanning the inner perimeter (150) of the cylindrical shell, with an angle β between the longitudinal axis (111) of the cylindrical housing (110) and a straight line (B) intersecting i) the longitudinal axis (111) at its intersection with the second inner surface (145) and ii) the intersection of the second inner surface (145) and the inner perimeter (150) of the cylindrical shell being in the range of from 55° to 80°, and the maximum of a perpendicular distance (b) between the straight line (B) and the surface of the second inner surface (145) being in the range of from 0.5 to 1 mm;a distance (d) between the first inner surface (141) and the second inner surface (145) at the inner perimeter (150) of the cylindrical shell being in the range of from 2 to 3 mm; and a minimal distance between the second section (143) of the first inner surface (141) and the second inner surface (145) being not less than 1 mm.
- The device of claim 1, wherein the maximum of the perpendicular distance (a) is (0.5 ± 0.05) mm; the maximum of the perpendicular distance (b) is (0.5 ± 0.05) mm; and the minimal distance between the second section (143) of the first inner surface (141) and the second inner surface (145) is (1 ± 0.1) mm.
- The device of claim 1 or 2, wherein the radius of curvature of the second inner surface (145) at the center of the second inner surface (145) is smaller than the radius of curvature opposite the second section (143) of the first inner surface (141).
- The device of any one of claims 1 to 3, wherein the first section (142) of the first inner surface (141) takes the form of a truncated cone with an aperture in the range of from 0.1° to 2°.
- The device of any one of claims 1 to 4, wherein the rotationally symmetric blood duct (140) is formed by assembling a first component part (301) having an outer surface that provides the first inner surface (141) of the blood duct (140) and a second component part (302) having an outer surface that provides the second inner surface (145) of the blood duct (140).
- The device of claim 5, wherein the outer surface of the first component part which provides the first inner surface (141) of the blood duct (140) features at least three protrusions and the outer surface of the second component part which provides the second inner surface (141) of the blood duct (140) features corresponding depressions; and the protrusions and corresponding depressions are configured to interact upon assembly of the first and second component parts and determine the spacing between the first and second inner surfaces (141, 145) of the blood duct (140).
- The device of claim 5, wherein the outer surface of the first component part which provides the first inner surface (141) of the blood duct (140) features at least three depressions (310) and the outer surface of the second component part which provides the second inner surface (141) of the blood duct (140) features corresponding protrusions (311); and the depressions (310) and corresponding protrusions (311) are configured to interact upon assembly of the first and second component parts and determine the spacing between the first and second inner surfaces (141, 145) of the blood duct (140).
- The device of any one of claims 5 to 7, wherein the first and second component parts are comprised of polycarbonate.
- The diffusion device of any one of claims 1 to 8, additionally comprising a second end cap (500) sealing a second mouth of the housing (110).
- The diffusion device of any one of claims 1 to 9, wherein the semi-permeable hollow fiber membranes (120) are impermeable to liquids and permeable to gases.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL18215661.2T PL3669971T3 (en) | 2018-12-21 | 2018-12-21 | Diffusion device |
EP18215661.2A EP3669971B1 (en) | 2018-12-21 | 2018-12-21 | Diffusion device |
ES18215661T ES2984921T3 (en) | 2018-12-21 | 2018-12-21 | Diffusion device |
JP2021535659A JP7457711B2 (en) | 2018-12-21 | 2019-12-20 | Diffusion Device |
US17/415,288 US12337088B2 (en) | 2018-12-21 | 2019-12-20 | Diffusion device |
CN201980085082.5A CN113226521B (en) | 2018-12-21 | 2019-12-20 | Diffusion device |
PCT/EP2019/086512 WO2020127865A1 (en) | 2018-12-21 | 2019-12-20 | Diffusion device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18215661.2A EP3669971B1 (en) | 2018-12-21 | 2018-12-21 | Diffusion device |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3669971A1 true EP3669971A1 (en) | 2020-06-24 |
EP3669971B1 EP3669971B1 (en) | 2024-05-22 |
Family
ID=65030876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18215661.2A Active EP3669971B1 (en) | 2018-12-21 | 2018-12-21 | Diffusion device |
Country Status (7)
Country | Link |
---|---|
US (1) | US12337088B2 (en) |
EP (1) | EP3669971B1 (en) |
JP (1) | JP7457711B2 (en) |
CN (1) | CN113226521B (en) |
ES (1) | ES2984921T3 (en) |
PL (1) | PL3669971T3 (en) |
WO (1) | WO2020127865A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3711695A1 (en) * | 1987-04-07 | 1988-10-27 | Akzo Gmbh | Distribution cap for a device for the extracorporal treatment of blood or its components |
US7871566B2 (en) * | 2005-08-18 | 2011-01-18 | Ilias-Medical Gmbh | Device for enriching and/or depleting materials in a liquid |
US8647569B1 (en) * | 2005-04-21 | 2014-02-11 | ALung Technologies, Inc | Paracorporeal respiratory assist lung |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2374932A1 (en) * | 1976-12-24 | 1978-07-21 | Rhone Poulenc Ind | HOLLOW FIBER APPARATUS, USABLE IN PARTICULAR AS AN ARTIFICIAL KIDNEY |
US4642089A (en) * | 1985-01-29 | 1987-02-10 | Shiley, Inc. | Unitary venous return reservoir with cardiotomy filter |
JPS62172964A (en) * | 1986-01-28 | 1987-07-29 | テルモ株式会社 | Hollow yarn type artificial organ and its production |
US5240677A (en) * | 1989-01-26 | 1993-08-31 | Shiley, Inc. | Hollow fiber blood oxygenator |
JPH0475664A (en) * | 1990-07-17 | 1992-03-10 | Ube Ind Ltd | model artificial lung |
US5263982A (en) * | 1990-03-14 | 1993-11-23 | Ube Industries, Ltd. | Hollow fiber membrane type artificial lung |
US5304312A (en) * | 1992-07-27 | 1994-04-19 | Eastman Kodak Company | Filter assembly includng filter unit having deformable sealing end caps |
US5266265A (en) * | 1992-10-08 | 1993-11-30 | Baxter International, Inc. | Modular disposable blood oxygenator/heat exchanger with durable heat source component, selectively including rotary or ventricular blood pump, venous reservoir, and auxiliary heat exchange component |
JP3617999B2 (en) * | 1993-08-06 | 2005-02-09 | 日機装株式会社 | Artificial cardiopulmonary apparatus and method for arranging centrifugal pump device in cardiopulmonary apparatus |
DE59600309D1 (en) * | 1995-09-25 | 1998-08-06 | Medos Medizintechnik Gmbh | Device for the treatment of liquids, in particular blood |
AU733288B2 (en) * | 1996-01-11 | 2001-05-10 | Medtronic, Inc. | Blood oxygenator with heat exchanger |
AU3971399A (en) * | 1998-05-08 | 1999-11-29 | Baxter International Inc. | Low prime membrane oxygenator with integrated heat exchanger/reservoir |
DE102006036948A1 (en) * | 2006-08-06 | 2008-02-07 | Akdis, Mustafa, Dipl.-Ing. | blood pump |
ES2581989T3 (en) * | 2007-01-13 | 2016-09-08 | 3M Innovative Properties Company | Device for the separation of leukocytes from the blood |
WO2008088293A1 (en) * | 2007-01-18 | 2008-07-24 | Hyflux Membrane Manufacturing (S) Pte Ltd | Membrane contactor |
KR20090118536A (en) * | 2008-05-14 | 2009-11-18 | 탑엠앤에이 주식회사 | Hemodialysis Device |
PT2560747E (en) * | 2010-07-07 | 2015-06-25 | Siemens Ag | Pressure vessel with multi membrane modules in parallel |
EP2524712B1 (en) * | 2011-05-17 | 2018-12-12 | Sorin Group Italia S.r.l. | Blood processing unit with cross blood flow |
US8795591B2 (en) * | 2011-01-27 | 2014-08-05 | Medtronic, Inc. | Dual outlet oxygenator for treating blood in an extracorporeal blood circuit |
CN103998116A (en) * | 2011-12-19 | 2014-08-20 | 东丽株式会社 | Hollow fiber membrane module and casing tube used for same |
CN202740496U (en) * | 2012-06-21 | 2013-02-20 | 甘布罗伦迪亚股份公司 | Capillary dialyzer |
WO2017051600A1 (en) | 2015-09-25 | 2017-03-30 | テルモ株式会社 | Artificial lung |
JP7053630B2 (en) * | 2016-09-22 | 2022-04-12 | クリストファー, ジェイ プロット, | Equipment and methods for in vitro conditioning of blood |
CN107485744B (en) * | 2017-09-12 | 2019-08-30 | 东莞科威医疗器械有限公司 | Membrane oxygenator |
-
2018
- 2018-12-21 PL PL18215661.2T patent/PL3669971T3/en unknown
- 2018-12-21 ES ES18215661T patent/ES2984921T3/en active Active
- 2018-12-21 EP EP18215661.2A patent/EP3669971B1/en active Active
-
2019
- 2019-12-20 WO PCT/EP2019/086512 patent/WO2020127865A1/en active IP Right Grant
- 2019-12-20 JP JP2021535659A patent/JP7457711B2/en active Active
- 2019-12-20 CN CN201980085082.5A patent/CN113226521B/en active Active
- 2019-12-20 US US17/415,288 patent/US12337088B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3711695A1 (en) * | 1987-04-07 | 1988-10-27 | Akzo Gmbh | Distribution cap for a device for the extracorporal treatment of blood or its components |
US8647569B1 (en) * | 2005-04-21 | 2014-02-11 | ALung Technologies, Inc | Paracorporeal respiratory assist lung |
US7871566B2 (en) * | 2005-08-18 | 2011-01-18 | Ilias-Medical Gmbh | Device for enriching and/or depleting materials in a liquid |
Also Published As
Publication number | Publication date |
---|---|
JP7457711B2 (en) | 2024-03-28 |
US20220054722A1 (en) | 2022-02-24 |
CN113226521A (en) | 2021-08-06 |
JP2022515149A (en) | 2022-02-17 |
US12337088B2 (en) | 2025-06-24 |
PL3669971T3 (en) | 2024-10-14 |
EP3669971B1 (en) | 2024-05-22 |
CN113226521B (en) | 2024-03-15 |
WO2020127865A1 (en) | 2020-06-25 |
ES2984921T3 (en) | 2024-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5192499A (en) | Fluid processing apparatus and artificial lung | |
EP0525317B1 (en) | An apparatus for effecting mass and/or heat transfer | |
US5817278A (en) | Blood oxygenator and method of oxygenating blood | |
EP0046583B1 (en) | Hollow fiber-type artificial lung having enclosed heat exchanger | |
US10286137B2 (en) | Oxygenator module, oxygenator and production method | |
US4808378A (en) | Blood oxygenator | |
US5733398A (en) | Efficient methods of manufacturing hollow fiber exchangers | |
JP4366268B2 (en) | Artificial lung | |
EP0297410A2 (en) | Heat and material exchangers | |
JP4397485B2 (en) | Filter device | |
US20150174311A1 (en) | Partial Radial Heat Exchanger and Oxygenator | |
EP0548065B1 (en) | Cylindrical blood heater/oxygenator | |
EP3669971A1 (en) | Diffusion device | |
EP0621047A2 (en) | Hollow fibre blood oxygenator | |
CN112773961A (en) | Oxygenator, oxygenator hollow fiber membrane woven assembly and forming method thereof | |
US5762875A (en) | Core structure for blood oxygenators | |
JP4892589B2 (en) | Artificial lung | |
US20230226495A1 (en) | Diffusion device | |
EP0222032B1 (en) | Blood oxygenator | |
JP4362432B2 (en) | Hollow fiber type module | |
EP0681040B1 (en) | An exchange structure, for example for biomedical equipment | |
CN112472896B (en) | An obliquely reduced shell and a dialyzer having the shell | |
JP2001129368A (en) | Gas-liquid separation module | |
WO2025070453A1 (en) | Artificial lung | |
JPH0819601A (en) | Artificial lung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201126 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230309 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTG | Intention to grant announced |
Effective date: 20240409 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602018069731 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20240522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240922 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240923 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1688328 Country of ref document: AT Kind code of ref document: T Effective date: 20240522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240923 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240822 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240922 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240823 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240822 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2984921 Country of ref document: ES Kind code of ref document: T3 Effective date: 20241031 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20241121 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20241126 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20241122 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20241121 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CZ Payment date: 20241127 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20241121 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20241127 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602018069731 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20250102 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
26N | No opposition filed |
Effective date: 20250225 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240522 |